Skip to main content
The Journal of Neuroscience logoLink to The Journal of Neuroscience
. 1996 Feb 15;16(4):1308–1316. doi: 10.1523/JNEUROSCI.16-04-01308.1996

Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody

L LeSauteur 1, S Maliartchouk 1, H Le Jeune 1, R Quirion 1, HU Saragovi 1
PMCID: PMC6578545  PMID: 8778282

Abstract

Monoclonal antibody (mAb) 5C3 directed against human p140 TrkA is a structural and functional mimic of nerve growth factor (NGF) and an artificial receptor agonist. mAb 5C3 binds in the NGF-docking site and, like NGF, it promotes TrkA internalization, TrkA and phosphatidylinositol-3 kinase tyrosine phosphorylation, and increased transformation of TrkA-expressing fibroblasts. More important, mAb 5C3 protects human TrkA-expressing cells from apoptotic death in serum-free media. Interestingly, agonistic activity is observed with monomeric F(ab) 5C3 fragments. mAb 5C3 (Kd approximately 2 nM) was used to study features of ligand binding by TrkA and the distribution of TrkA protein in normal human brain.


Articles from The Journal of Neuroscience are provided here courtesy of Society for Neuroscience

RESOURCES